
Quarterly report 2025-Q3
added 11-12-2025
TherapeuticsMD Net Debt 2011-2026 | TXMD
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt TherapeuticsMD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.68 M | -29.3 M | 125 M | 159 M | 44.5 M | -88.2 M | -127 M | -132 M | -64.7 M | -51.4 M | -54.2 M | 2.04 M | 2.02 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 159 M | -132 M | -16.2 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Drug manufacturers industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
-6.59 M | - | 7.5 % | $ 6.35 M | ||
|
Alimera Sciences
ALIM
|
-11.2 M | - | - | $ 142 M | ||
|
Aerie Pharmaceuticals
AERI
|
-11.1 M | - | - | $ 754 M | ||
|
Agile Therapeutics
AGRX
|
-676 K | - | 10.11 % | $ 58.2 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
-22.5 M | - | 0.86 % | $ 117 M | ||
|
Eagle Pharmaceuticals
EGRX
|
2.43 M | - | -39.89 % | $ 27.7 M | ||
|
Perrigo Company plc
PRGO
|
3.1 B | $ 9.78 | 1.45 % | $ 1.35 B | ||
|
Aurora Cannabis
ACB
|
285 M | $ 3.45 | 3.77 % | $ 86.3 M | ||
|
Catalent
CTLT
|
4.58 B | - | - | $ 11.5 B | ||
|
Rockwell Medical
RMTI
|
691 K | $ 1.05 | 1.46 % | $ 24.5 M | ||
|
Athenex
ATNX
|
-28.3 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
-49.7 M | - | - | $ 2.06 B | ||
|
Cronos Group
CRON
|
-1.07 B | $ 2.63 | 1.74 % | $ 1.39 B | ||
|
DURECT Corporation
DRRX
|
-10.4 M | - | - | $ 50.1 M | ||
|
Emergent BioSolutions
EBS
|
338 M | $ 8.19 | 2.18 % | $ 419 M | ||
|
Endo International plc
ENDP
|
7.37 B | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
-2.96 M | - | - | $ 36.6 M | ||
|
Sundial Growers
SNDL
|
-28.4 M | $ 1.37 | -0.36 % | $ 3.37 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
-931 M | - | -0.1 % | $ 2.03 B | ||
|
Sonoma Pharmaceuticals
SNOA
|
-5.29 M | $ 2.28 | -2.78 % | $ 2.83 M | ||
|
HEXO Corp.
HEXO
|
-150 M | - | 2.45 % | $ 38.1 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
-12.7 M | $ 3.34 | 6.71 % | $ 47 M | ||
|
Neoleukin Therapeutics
NLTX
|
-101 M | - | - | $ 193 M | ||
|
Bausch Health Companies
BHC
|
21.1 B | $ 5.07 | 1.3 % | $ 1.85 B | ||
|
PetIQ
PETQ
|
329 M | - | 1.64 % | $ 400 M | ||
|
OptiNose
OPTN
|
-72.2 M | - | - | $ 1.08 B | ||
|
PLx Pharma
PLXP
|
-21.8 M | - | -27.8 % | $ 2.56 M | ||
|
ProPhase Labs
PRPH
|
-6.41 M | - | - | $ 5.07 M | ||
|
Pacira BioSciences
PCRX
|
317 M | $ 23.46 | 1.12 % | $ 1.08 B | ||
|
Veru
VERU
|
-20.9 M | $ 2.29 | - | $ 309 M | ||
|
Evolus
EOLS
|
94.8 M | $ 4.37 | -1.35 % | $ 282 M | ||
|
Radius Health
RDUS
|
-111 M | - | - | $ 1.42 B | ||
|
Solid Biosciences
SLDB
|
-38.7 M | $ 7.2 | 7.78 % | $ 630 M | ||
|
Relmada Therapeutics
RLMD
|
-2.5 M | $ 6.55 | 7.38 % | $ 259 M | ||
|
Tilray
TLRY
|
14.4 M | $ 6.93 | 4.05 % | $ 4.28 B | ||
|
OrganiGram Holdings
OGI
|
90.7 M | $ 1.38 | 2.8 % | $ 402 M | ||
|
SCYNEXIS
SCYX
|
-19.1 M | $ 0.88 | -2.2 % | $ 43.9 M | ||
|
Jupiter Wellness
JUPW
|
-21.7 K | - | - | $ 33.6 M | ||
|
Viatris
VTRS
|
16.8 B | $ 13.51 | 1.09 % | $ 16.2 B | ||
|
China Pharma Holdings
CPHI
|
-4.73 M | $ 0.6 | 2.41 % | $ 10.5 M | ||
|
cbdMD
YCBD
|
-521 K | $ 0.79 | 2.74 % | $ 3.41 M | ||
|
Assertio Holdings
ASRT
|
29.1 M | $ 18.59 | 12.6 % | $ 119 M | ||
|
Lannett Company
LCI
|
529 M | - | 1.15 % | $ 7.11 M | ||
|
Harrow Health
HROW
|
178 M | $ 36.23 | 2.93 % | $ 1.33 B | ||
|
Organogenesis Holdings
ORGO
|
-131 M | $ 2.4 | -0.21 % | $ 316 M | ||
|
Canopy Growth Corporation
CGC
|
193 M | $ 0.98 | 1.86 % | $ 105 M | ||
|
Recro Pharma
REPH
|
-6.65 M | - | -4.76 % | $ 65.3 M | ||
|
Tricida
TCDA
|
-7.08 M | - | - | $ 3.25 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
-50.3 M | - | - | $ 55.5 M |